Memantina Zidrium Teva

Memantine Hydrochloride, the active ingredient in Memantina Zidrium Teva, is a NMDA receptor antagonist presented as a tablet for oral use. It is used to treat cognitive symptoms of Alzheimer’s disease in adult patients. GNH USA supplies Memantina Zidrium Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride acts on the glutamatergic pathway and is indicated for Alzheimer’s disease. - Alzheimer’s disease (mild to moderate): may improve memory, thinking and daily functioning. - Alzheimer’s disease (severe): may help maintain functional abilities and slow decline.

Memantina Zidrium Teva may cause a range of adverse reactions.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling unusually tired. - Nausea: mild stomach upset. - Cough: non‑productive throat irritation.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Hallucinations: visual or auditory disturbances. - Severe rash or skin reactions: including Stevens‑Johnson syndrome. - Hyponatremia: low blood sodium levels. - Liver enzyme elevation: abnormal liver function tests. - Mood changes: depression or suicidal thoughts.

Before prescribing Memantina Zidrium Teva, clinicians should consider several safety aspects. - Renal impairment: adjust dose in moderate to severe kidney disease. - History of seizures: monitor closely for increased seizure risk. - Cardiovascular disease: use cautiously in patients with unstable conditions. - Concomitant CNS depressants: may enhance dizziness or sedation. - Pregnancy and breastfeeding: only if potential benefit outweighs risk. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Memantina Zidrium Teva can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS effects and risk of severe dizziness.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): may affect overall cognitive response. - Diuretics: potential for electrolyte imbalance, especially hyponatremia. - CNS depressants (e.g., benzodiazepines): may enhance sedation and dizziness.